Defibrotide News and Research

RSS
Clinical trial to test the efficacy of defibrotide medicine for reducing COVID-19 death rate

Clinical trial to test the efficacy of defibrotide medicine for reducing COVID-19 death rate

International researchers succeed in stopping growth of mesothelioma in model animals

International researchers succeed in stopping growth of mesothelioma in model animals

FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

Three abstracts on Defibrotide presented at ASH Annual Meeting

Three abstracts on Defibrotide presented at ASH Annual Meeting

Gentium to present three abstracts on Defibrotide at American Society of Hematology

Gentium to present three abstracts on Defibrotide at American Society of Hematology

Gentium third quarter total revenues increase to EUR 5.91 million

Gentium third quarter total revenues increase to EUR 5.91 million

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Gentium second-quarter total revenues increase to EUR 7.55 million

Gentium second-quarter total revenues increase to EUR 7.55 million

Gentium first-quarter net loss decreases to EUR 0.03 million

Gentium first-quarter net loss decreases to EUR 0.03 million

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

China Biologic Products' fourth quarter revenue rises 185.6%

China Biologic Products' fourth quarter revenue rises 185.6%

Investment report on Gentium from InvestorSoup.com

Investment report on Gentium from InvestorSoup.com

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award